2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
- Status
- WITHDRAWN
- Phase
- PHASE2
Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients
- Status
- COMPLETED
- Phase
- N/A
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Status
- COMPLETED
- Phase
- PHASE2
Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies
- Status
- COMPLETED
- Phase
- N/A
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
- Status
- TERMINATED
- Phase
- PHASE2
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment
- Status
- COMPLETED
- Phase
- PHASE2
Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- N/A
Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple
- Status
- UNKNOWN
- Phase
- N/A
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE4
Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)
- Status
- UNKNOWN
- Phase
- PHASE1
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE1
Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery
- Status
- COMPLETED
- Phase
- NA
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2